Evaxion A/S Receives 2026 Prix Galien UK Award for AI-Immunology™ Platform

On June 12, 2026, Evaxion A/S (NASDAQ: EVAX) announced that it has been awarded the 2026 Prix Galien UK Award for 'Best digital health solution' for its proprietary AI-Immunology™ platform. This marks the second recognition for the company from the Galien Prix Foundation within a year, following a previous award in December 2025 for 'Best Medical Technology / AI Advances' in the Nordic and high-growth European and Middle Eastern regions. The award committee, comprised of 12 healthcare experts, selected Evaxion from a pool of 10 candidates based on the platform's innovation in scientific development, clinical application, and potential impact on human health. The AI-Immunology™ platform is designed to decode the human immune system to discover and develop novel vaccine candidates for cancer and infectious diseases. While the award serves as external validation of Evaxion's technology, the filing does not disclose new clinical data or financial updates.